Juno Pharmaceuticals Corp. is pleased to announce that it has secured a significant growth capital investment from New-York-based global healthcare equity firm, Signet Healthcare Partners.
Through this investment, Signet will help fuel the continued rapid acceleration of Juno’s complex and high-value generic and biosimilar portfolio in Canada, while also joining the company’s Board of Directors.
James Gale, Managing Director of Signet said, “We are very pleased with the opportunity to partner with the Juno management team. They have decades of pharmaceutical industry experience and have built a growing business. They have done so through astute product selection and a disciplined approach to building their pipeline. We look forward to contributing to this effort.”
Ian Jacobson, CEO of Juno’s international operations commented on the investment, noting “we believe Signet will further enhance Juno’s already strong growth profile given their extensive experience in pharma, and specifically with generics. We look forward to working with the Signet team building Juno into one of the leading generic pharmaceutical companies in Canada.”